Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yun Fan

Showing results (851-860 of 920) with videos related to

Pageof 92
Sort By:
Zhonghua Xin Xue Guan Bing Za Zhi|December 22, 2009
[Novel MYBPC3 mutations in Chinese patients with hypertrophic cardiomyopathy]Zhan-feng Ma, Wen-ling Liu, Da-yi Hu, et al.
The Lancet. Respiratory Medicine|September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Science Immunology|May 10, 2024
Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunityChuan Qin, Min Zhang, Da-Peng Mou, et al.
Hepatology International|July 24, 2015
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateYun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
The Lancet Regional Health. Western Pacific|April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic <i>MET</i> exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of ChinaShun Lu, Qing Zhou, Xiaoqing Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)Caicun Zhou, Lin Wu, Yun Fan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2018
Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular CarcinomaWei Guo, Yun-Fan Sun, Min-Na Shen, et al.
Pageof 92

Showing results (851-860 of 920) with videos related to

Sort By:
Pageof 92
Zhonghua Xin Xue Guan Bing Za Zhi|December 22, 2009
[Novel MYBPC3 mutations in Chinese patients with hypertrophic cardiomyopathy]Zhan-feng Ma, Wen-ling Liu, Da-yi Hu, et al.
The Lancet. Respiratory Medicine|September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Science Immunology|May 10, 2024
Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunityChuan Qin, Min Zhang, Da-Peng Mou, et al.
Hepatology International|July 24, 2015
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateYun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
The Lancet Regional Health. Western Pacific|April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic <i>MET</i> exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of ChinaShun Lu, Qing Zhou, Xiaoqing Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)Caicun Zhou, Lin Wu, Yun Fan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2018
Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular CarcinomaWei Guo, Yun-Fan Sun, Min-Na Shen, et al.
Pageof 92